HONG KONG, March 13, 2025 /PRNewswire/ — Kerry Logistics Network Limited (‘KLN’; Stock Code 0636.HK), through its subsidiary, Kerry Pharma, and Teva Pharmaceutical Hong Kong Limited (‘Teva’) entered into an exclusive agreement for fourth-party logistics (4PL) distribution services in Hong Kong, Macau and other markets in the Greater Bay Area. As the sole distributor of the complete range of Teva’s products, Kerry Pharma manages Teva’s supply chains with end-to-end pharmaceutical logistics solutions, ensuring seamless distribution and stable product availability at all times.

The collaboration serves to strengthen KLN’s position and deepen its foothold in the pharmaceutical logistics sector, which is essential to public health, while enabling Teva to focus on its core business with strengthened logistics support, enhanced operational efficiency and swift market responsiveness.

KLN’s dedicated 4PL fulfilment solutions cover inbound logistics, warehousing, distribution, billing, reporting and exports, managing a portfolio of 190 SKUs and over 3,000 delivery points, from hospital pharmacies, clinics to drug stores and key chain channels. Leveraging its multi-temperature storage capability, KLN maintains strict temperature controls for Teva’s general pharmaceuticals and sensitive items, including dangerous drugs, ensuring complete cold chain integrity for all products. For deliveries within the Greater Bay Area, KLN offers ocean freight and air freight, respectively, supported by KLN’s cold chain solutions.

Samuel Lau, Managing Director – Integrated Logistics Asia of KLN, said, “This exclusive partnership not only underscores KLN’s commitment to delivering high-quality services, but also enhances our ability to manage Teva’s extensive product range effectively. As the sole distributor of Teva’s product range, we also handle the crucial regulatory requirements such as import licenses and liaison with the Department of Health, ensuring hassle-free customer experience for Teva. This exclusivity also enables us to foster a deeper collaboration with Teva, aligning our goals and resources to better serve our customers and respond swiftly to market demands.”

Theodor Wee, General Manager of Teva Greater China, said, “The stable supply of medicines is crucial to patient health, and Teva is always committed to exploring innovative initiatives to improve patient access to medicines continuously. This collaboration also exemplifies Teva’s global ‘Pivot to Growth’ strategy. In the future, we will accelerate to bring more medicines that will meet the evolving needs of patients. Teva looks forward to partnering with Kerry Pharma to promote medical integration and innovation in the Greater Bay Area, leveraging each other’s strengths as a model of cooperation.”

About Kerry Logistics Network Limited (Stock Code 0636.HK)

KLN is an Asia-based, global 3PL with a highly diversified business portfolio and extensive coverage in Asia. It offers a broad range of supply chain solutions from integrated logistics, international freight forwarding (air, ocean, road, rail and multimodal) and e-commerce to industrial project logistics and infrastructure investment.

With a global presence across 59 countries and territories, KLN has established a solid foothold in half of the world’s emerging markets. Its diverse infrastructure, extensive coverage in international gateways and local expertise span across the Mainland of China, India, Southeast Asia, the CIS, Middle East, LATAM and other locations.

KLN generated a revenue of over HK$47.4 billion in 2023. It is listed on the Hong Kong Stock Exchange and is a constituent of the Hang Seng Corporate Sustainability Benchmark Index.

About Teva

Teva Pharmaceutical Industries Ltd. is a different kind of global pharmaceutical leader, one that operates across the full spectrum of innovation to reliably deliver medicines to patients worldwide. For over 120 years, Teva’s commitment to bettering health has never wavered. Today, the company’s global network of capabilities enables its 37,000 employees across 57 markets to advance health by developing medicines for the future while championing the production of generics and biologics. If patients have a need, we’re already working to address it.

Teva China has offices in Shanghai, Beijing, and Hong Kong. Teva China has established strong collaboration with partners across various sectors to enhance the product accessibility and affordability.

To learn more about how Teva is all in for better health, visit www.tevapharm.com.

SOURCE Kerry Logistics Network Limited